Brooks Laboratories Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹67.20
-0.10-0.15% (1D)
As on 20 Nov 2026 at 15:58
As of 20 Nov 2026 at 15:58, Brooks Laboratories Ltd is trading at ₹67.20. The 52-week range stands at ₹36.30–₹108.70, with a market cap of ₹198.22 crore. At a P/E of 68.66 and a dividend yield of 0.00%, it is a small-cap stock in the Pharmaceuticals sector.

BROOKS Price Chart

Market Cap
₹198.22 Cr
PE Ratio
68.66
ROCE
1.83%

Brooks Laboratories Ltd Performance

Brooks Laboratories Ltd Fundamentals

Know More
Market Cap₹198.22 Cr
ROE1.51%
P/E Ratio (TTM)68.66
EPS (TTM)₹0.98
P/B Ratio1.03
Dividend Yield0.00%
Industry P/E91.72
Book Value₹65.26
Debt to Equity0.04
Face Value₹10

Brooks Laboratories Ltd Shareholding Pattern

Know More
Promoter52.6%
Foreign Institutions0%
Mutual Funds9.9%
Domestic Institutions0%
Public37.4%

Brooks Laboratories Ltd Financial Statements

Know More
No data for this view.

Brooks Laboratories Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Brooks Laboratories

Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment. It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India. With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a world's largest dedicated EU certified plant at Vadodara. In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production. In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan. In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity. On 7 March 2017, Brooks Laboratories' world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review. The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line. The Company started production and sales at its manufacturing facility in Vadodara in 2019-20. The joint venture company, Brooks Steriscience Limited, secured approval from the USFDA for Meropenem for Injection and commenced its product supply in FY 2023.

Parent Organisation—
Founded2002
Managing Director—
NSE SymbolBROOKS

Brooks Laboratories Ltd Resistance and Support levels

R371.23R269.89R169.07S166.40S265.58S364.2567.20

Brooks Laboratories Ltd Technicals

Current Price
₹67.20 ₹0.10 (-0.15%)
Bearish
1
Bullish
11
  • 20 Day2.9%
  • 50 Day5.0%
  • 100 Day4.3%
  • 200 Day4.6%

Brooks Laboratories Ltd Latest News

View More
12 NOV 2026 | Thursday
CARE Ratings upgraded Brooks Laboratories' bank facilities, citing Rs 86.26 crore operations in FY26
09 OCT 2026 | Friday
Brooks Laboratories Limited confirms regulatory compliance for the quarter ended September 30
17 AUG 2026 | Monday
Brooks Laboratories Limited announced a book closure from August 27 to September 3, 2026
06 AUG 2026 | Thursday
Brooks Laboratories to review quarterly results at board meeting on August 13, 2026
12 JUN 2026 | Friday
Brooks Laboratories AGM scheduled
25 MAY 2026 | Monday
Brooks Laboratories to convene board meeting

2026

Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Brooks Laboratories Ltd is ₹67.20 as of 20 Nov 2026 at 15:58.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now